Harlan Waksal
CIK: 0001449008
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)1 (50.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
About Waksal Harlan
Waksal Harlan (SEC CIK 0001449008) files insider reports with the SEC as Freenome, Inc. (FRNM) and Executive Chair of Lyra Therapeutics, Inc. (LYRA).
Signal8 holds 2 ownership filings by Waksal Harlan, all Form 4s, filed between Dec 11, 2024 and Jul 29, 2026. Those filings report 2 transactions, from Dec 9, 2024 to Jul 20, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Waksal Harlan's filings is in NEW YORK, NY.
Recent filings by Waksal Harlan
Other insiders filing for Freenome, Inc. (FRNM)
- Elliott Aaron Matthew, Chief Executive Officer
- Nuechterlein Carole, Director
- Costello Ann Catherine, Director
- VAN OORT DOUGLAS M, Director
- Le Linh H., Chief Financial Officer
- PAKIANATHAN DEEPIKA, Director